GERON

Geron is a late-stage biopharmaceutical company with a mission to extend and enhance the lives of patients living with hematologic malignancies. Our first-in-class telomerase inhibitor, imetelstat, has demonstrated strong evidence of disease modification in Phase 2 trials... Geron is focused on the development and potential commercialization of imetelstat and currently has two Phase 3 clinical trials ongoing: IMerge in lower risk myelodysplastic syndromes (LR MDS) and IMpactMF in relapsed/refractory myelofibrosis (MF). These indications represent potential multi-billion-dollar market opportunities. We have an experienced and knowledgeable management team and employee base to execute and deliver on our mission... Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives.

Also known as: Geron Corporation

Primary location: Foster City United States